(VIANEWS) – The Market ended the session with MITHRA (MITRA.BR) rising 14.56% to €3.54 on Wednesday, after two successive sessions in a row of gains. BEL 20 dropped 0.08% to €3,849.32, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.
MITHRA’s last close was €3.09, 81.14% below its 52-week high of €16.38.
About MITHRA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-2.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.93%.
More news about MITHRA (MITRA.BR).
